Trade Praxis Precision Medicines Inc - PRAXus CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.58
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022207 %(-$0.44)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02221%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000015 %(-$0.00)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00002%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022207 %
  (-$0.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000015 %
  (-$0.00)

Key Stats

• Prev. Close: 281.6
• Open: 282.49
• 1-Year Change: 476.51%
• Day's Range: 278.55 - 283.18

Trade Praxis Precision Medicines Inc - PRAXus

About Praxis Precision Medicines Inc

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Praxis Precision Medicines Inc revenues was not reported. Net loss applicable to common stockholders increased from $70.3M to $167.1M. Higher net loss reflects Stock based compensation increase from $43.6M to $89.2M (expense), General and administrative increase from $13.1M to $33.7M (expense), Stock-based Compensation in SGA increase from $3.9M to $13.3M (expense).